<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aducanumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aducanumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Aducanumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="131829" href="/d/html/131829.html" rel="external">see "Aducanumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F58643151"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Amyloid related imaging abnormalities:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Monoclonal antibodies directed against aggregated forms of beta amyloid, including aducanumab, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur. Serious intracerebral hemorrhages, some of which have been fatal, have been observed in patients treated with this class of medications.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients who are apolipoprotein E ε4 (ApoE ε4) homozygotes (~15% of Alzheimer disease patients) treated with this class of medications, including aducanumab, have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed they can still be treated with aducanumab; however, it cannot be determined if they are ApoE ε4 homozygotes and at higher risk for ARIA.</p>
<p style="text-indent:-2em;margin-left:2em;">Consider the benefit of aducanumab for the treatment of Alzheimer disease and potential risk of serious adverse events associated with ARIA when deciding to initiate treatment with aducanumab.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55871549"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aduhelm</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55855111"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-Amyloid Monoclonal Antibody;</li>
<li>
                        Immune Globulin;</li>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F55871846"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Confirm the presence of amyloid beta pathology prior to treatment initiation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3041b3d-3f11-47c1-815e-01b475c1f691">Alzheimer disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alzheimer disease: IV:</b> Initial: Dosing based on actual body weight: 1 mg/kg once every 4 weeks for infusions 1 and 2; 3 mg/kg once every 4 weeks for infusions 3 and 4; 6 mg/kg once every 4 weeks for infusions 5 and 6; maintenance dose: 10 mg/kg once every 4 weeks starting with infusion 7. Administer infusions at least 21 days apart.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed dose:</i> Administer as soon as possible and at least 21 days apart.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F55871848"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, aducanumab is not expected to undergo renal elimination.</p></div>
<div class="block doha drugH1Div" id="F55871849"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, aducanumab is not expected to undergo hepatic metabolism.</p></div>
<div class="block dot drugH1Div" id="F56833388"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Amyloid-Related Imaging Abnormalities – Edema (ARIA-E)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Severity of clinical symptoms</p></th>
<th align="center" colspan="3">
<p style="text-indent:0em;">ARIA-E severity on MRI</p></th></tr>
<tr>
<th align="center"></th>
<th align="center">
<p style="text-indent:0em;">Mild</p></th>
<th align="center">
<p style="text-indent:0em;">Moderate</p></th>
<th align="left">
<p style="text-indent:0em;">Severe</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Asymptomatic</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Continue current aducanumab dose and schedule.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold aducanumab until MRI shows radiographic resolution and symptoms (if present) resolve; consider follow-up MRI to assess for resolution 2 to 4 months after initial identification. May resume at same dose and titration prior to withholding therapy, as guided by clinical judgement.</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold aducanumab until MRI shows radiographic resolution and symptoms (if present) resolve; consider follow-up MRI to assess for resolution 2 to 4 months after initial identification. May resume at same dose and titration prior to withholding therapy, as guided by clinical judgement.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Mild</p></td>
<td align="center">
<p style="text-indent:0em;">Continue aducanumab dosing based on clinical judgement.</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold aducanumab until MRI shows radiographic resolution and symptoms (if present) resolve; consider follow-up MRI to assess for resolution 2 to 4 months after initial identification. May resume at same dose and titration prior to withholding therapy, as guided by clinical judgement.</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold aducanumab until MRI shows radiographic resolution and symptoms (if present) resolve; consider follow-up MRI to assess for resolution 2 to 4 months after initial identification. May resume at same dose and titration prior to withholding therapy, as guided by clinical judgement.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Moderate or severe</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold aducanumab until MRI shows radiographic resolution and symptoms (if present) resolve; consider follow-up MRI to assess for resolution 2 to 4 months after initial identification. May resume at same dose and titration prior to withholding therapy, as guided by clinical judgement.</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold aducanumab until MRI shows radiographic resolution and symptoms (if present) resolve; consider follow-up MRI to assess for resolution 2 to 4 months after initial identification. May resume at same dose and titration prior to withholding therapy, as guided by clinical judgement.</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold aducanumab until MRI shows radiographic resolution and symptoms (if present) resolve; consider follow-up MRI to assess for resolution 2 to 4 months after initial identification. May resume at same dose and titration prior to withholding therapy, as guided by clinical judgement.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Amyloid-Related Imaging Abnormalities – Hemosiderin (ARIA-H)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Clinical symptom severity</p></th>
<th align="center" colspan="3">
<p style="text-indent:0em;">ARIA-H severity on MRI</p></th></tr>
<tr>
<th align="center"></th>
<th align="center">
<p style="text-indent:0em;">Mild</p></th>
<th align="center">
<p style="text-indent:0em;">Moderate</p></th>
<th align="left">
<p style="text-indent:0em;">Severe</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Asymptomatic</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Continue current aducanumab dose and schedule.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold aducanumab until MRI shows radiographic stabilization and symptoms (if present) resolve; consider follow-up MRI to assess for resolution 2 to 4 months after initial identification. May resume at same dose and titration prior to withholding therapy, as guided by clinical judgement.</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold aducanumab until MRI shows radiographic stabilization and symptoms (if present) resolve. Use clinical judgement to determine whether to continue treatment or permanently discontinue aducanumab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Symptomatic</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold aducanumab until MRI shows radiographic stabilization and symptoms (if present) resolve; consider follow-up MRI to assess for resolution 2 to 4 months after initial identification. May resume at same dose and titration prior to withholding therapy, as guided by clinical judgement.</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold aducanumab until MRI shows radiographic stabilization and symptoms (if present) resolve; consider follow-up MRI to assess for resolution 2 to 4 months after initial identification. May resume dose at same and titration prior to withholding therapy, as guided by clinical judgement.</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold aducanumab until MRI shows radiographic stabilization and symptoms (if present) resolve. Use clinical judgement to determine whether to continue treatment or permanently discontinue aducanumab.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracerebral hemorrhage &gt;1 cm in diameter:</b> Withhold aducanumab until MRI shows radiographic stabilization and symptoms (if present) resolve. Use clinical judgement to determine whether to continue treatment or permanently discontinue aducanumab; in some studies, aducanumab was permanently discontinued in patients who developed intracerebral hemorrhage &gt;1 cm in diameter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35542991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35542991'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F55871847"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56250204"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Amyloid-related imaging abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amyloid-related imaging abnormalities (ARIA), including ARIA consistent with vasogenic edema and/or sulcal effusions (ARIA-E) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35099507','lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35099507','lexi-content-ref-21784348'])">Ref</a></span>) and ARIA with hemosiderin deposition (ARIA-H) characterized by superficial siderosis and <b>microhemorrhages</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35099507','lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35099507','lexi-content-ref-21784348'])">Ref</a></span>) have been reported with aducanumab therapy. Patients may develop ARIA-H with concomitant ARIA-E. In patients who developed ARIA (-E and/or -H) during aducanumab clinical trials, most cases were asymptomatic with mild to moderate radiographic severity; however, serious and/or fatal symptoms have been reported. Recurrent episodes have also been described and were less symptomatic than initial episodes. Clinical symptoms suggesting ARIA (-E and/or -H) may include <b>altered mental status</b>, abnormal gait, <b>confusion</b>, <b>delirium</b>, <b>disorientation</b>, dizziness, focal neurologic deficits, <b>headache</b>, nausea, <b>seizure</b>, and visual disturbance. Resolution of ARIA (-E and/or -H) occurred within 12 to 20 weeks in the majority of cases in clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; speculated that increased clearance of amyloid from parenchymal plaques into perivascular space may result in excess fluid shifts. This movement of amyloid into cerebral vessel walls may also increase vascular friability and permeability, thus impairing vessel wall integrity to permit small amounts of blood passage. Increased vascular permeability at which both fluid and red blood cells cross the vessel wall may suggest a common pathophysiologic mechanism for both ARIA-E and ARIA-H (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23578674','lexi-content-ref-35099507','lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23578674','lexi-content-ref-35099507','lexi-content-ref-21784348'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">ARIA-E: Dose-related; related to the pharmacologic action. Increased cerebrovascular permeability due to antibody binding to deposited amyloid-beta results in an increase in extracellular fluid volume and vasogenic edema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31827267','lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31827267','lexi-content-ref-21784348'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">ARIA-H: Dose-related; related to the pharmacologic action. Leakage of blood from a vessel into adjacent tissue parenchyma or subarachnoid space/periadvential compartments leaves residual deposits of iron in the form of hemosiderin, resulting in superficial siderosis and/or radiographic evidence of hemorrhage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21784348'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; ARIA may occur at any time during treatment, but most events occur within the first 8 doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">ARIA-E:</p>
<p style="text-indent:-2em;margin-left:8em;">• Apolipoprotein E ε4 carriers; specifically ApoE ε4 homozygotes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35099507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35099507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dose; risk increases with higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35099507','lexi-content-ref-31827267']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35099507','lexi-content-ref-31827267'])">Ref</a></span>) and during dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34747986']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34747986'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">ARIA-H: Microhemorrhages:</p>
<p style="text-indent:-2em;margin-left:8em;">• Apolipoprotein E ε4 carriers; specifically ApoE ε4 homozygotes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21784348'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Increasing age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21784348'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Greater number of microhemorrhages at baseline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31827267','lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31827267','lexi-content-ref-21784348'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults with cardiovascular risk factors and/or evidence of prior cerebrovascular event (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21784348'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant risk factors for intracerebral hemorrhages (prior cerebral hemorrhage &gt;1 cm, &gt;4 microhemorrhages, superficial siderosis, vasogenic edema, aneurysm, vascular malformation)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55862562"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults. ARIA-E: amyloid related imaging abnormalities-edema; ARIA-H: amyloid related imaging abnormalities-hemosiderin deposition.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemosiderosis (ARIA-H, including microhemorrhages and superficial siderosis: 15% to 19%)<span class="lexi-table-link-container"> (<a aria-label="Hemosiderosis table link" class="lexi-table-link" data-table-id="lexi-content-hemosiderosis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hemosiderosis')">table 1</a>)</span><span class="table-link" style="display:none;">Hemosiderosis</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hemosiderosis" frame="border" id="lexi-content-hemosiderosis" rules="all">
<caption>
<b>Aducanumab: Adverse Reaction: Hemosiderosis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,105</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,087</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ARIA-H microhemorrhage</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,105</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,087</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ARIA-H superficial siderosis</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Brain edema (ARIA-E, including sulcal effusion: 20% to 64%; higher in apolipoprotein E ε4 carriers)<span class="lexi-table-link-container"> (<a aria-label="Brain Edema table link" class="lexi-table-link" data-table-id="lexi-content-brain-edema" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-brain-edema')">table 2</a>)</span><span class="table-link" style="display:none;">Brain Edema</span>, falling (15%), headache (21%)<span class="lexi-table-link-container"> (<a aria-label="Headache table link" class="lexi-table-link" data-table-id="lexi-content-headache" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headache')">table 3</a>)</span><span class="table-link" style="display:none;">Headache</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Brain Edema" frame="border" id="lexi-content-brain-edema" rules="all">
<caption>
<b>Aducanumab: Adverse Reaction: Brain Edema</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">64%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ARIA-E; apolipoprotein E ε4 carriers; homozygotes</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,105</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,087</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ARIA-E; apolipoprotein E ε4 carriers; heterozygotes</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ARIA-E; apolipoprotein E ε4 non-carriers</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Headache" frame="border" id="lexi-content-headache" rules="all">
<caption>
<b>Aducanumab: Adverse Reaction: Headache</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,105</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,087</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered mental status (≤8%)<span class="lexi-table-link-container"> (<a aria-label="Altered Mental Status table link" class="lexi-table-link" data-table-id="lexi-content-altered-mental-status" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-altered-mental-status')">table 4</a>)</span><span class="table-link" style="display:none;">Altered Mental Status</span>, confusion (≤8%)<span class="lexi-table-link-container"> (<a aria-label="Confusion table link" class="lexi-table-link" data-table-id="lexi-content-confusion" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-confusion')">table 5</a>)</span><span class="table-link" style="display:none;">Confusion</span>, delirium (≤8%)<span class="lexi-table-link-container"> (<a aria-label="Delirium table link" class="lexi-table-link" data-table-id="lexi-content-delirium" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-delirium')">table 6</a>)</span><span class="table-link" style="display:none;">Delirium</span>, disorientation (≤8%)<span class="lexi-table-link-container"> (<a aria-label="Disorientation table link" class="lexi-table-link" data-table-id="lexi-content-disorientation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-disorientation')">table 7</a>)</span><span class="table-link" style="display:none;">Disorientation</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Altered Mental Status" frame="border" id="lexi-content-altered-mental-status" rules="all">
<caption>
<b>Aducanumab: Adverse Reaction: Altered Mental Status</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,105</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,087</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Defined as "confusion, delirium, altered mental status, disorientation"</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Confusion" frame="border" id="lexi-content-confusion" rules="all">
<caption>
<b>Aducanumab: Adverse Reaction: Confusion</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,105</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,087</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Defined as "confusion, delirium, altered mental status, disorientation"</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Delirium" frame="border" id="lexi-content-delirium" rules="all">
<caption>
<b>Aducanumab: Adverse Reaction: Delirium</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,105</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,087</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Defined as "confusion, delirium, altered mental status, disorientation"</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Disorientation" frame="border" id="lexi-content-disorientation" rules="all">
<caption>
<b>Aducanumab: Adverse Reaction: Disorientation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aducanumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,105</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,087</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Defined as "confusion, delirium, altered mental status, disorientation"</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Seizure (associated with ARIA)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Nervous system: Status epilepticus</p></div>
<div class="block coi drugH1Div" id="F55855050"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F55871828"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warning/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Confirm the presence of amyloid beta pathology prior to treatment initiation.</p></div>
<div class="block foc drugH1Div" id="F55871550"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aduhelm: Aducanumab-avwa 300 mg/3 mL (3 mL); Aducanumab-avwa 170 mg/1.7 mL (1.7 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F55871548"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55937482"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Aduhelm Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">170 mg/1.7 mL (per mL): $338.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/3 mL (per mL): $338.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F55871850"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Dilution required prior to administration. Allow refrigerated infusion bags to warm to room temperature prior to administering. Administer by IV infusion over ~60 minutes through an IV line containing a sterile, low-protein binding, 0.2 or 0.22 micron in-line filter. Discard unused portion.</p></div>
<div class="block meg drugH1Div" id="F55871824"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761178s011lbl.pdf%23page%3D26&amp;token=OKWuU515UFB2SyKxCl4t6YXzlKURpAqrB5pEtaYTSXxXmatSFjbmhuizYwj04KI%2FClvAvS33aYogkwD3H6D27R1FrTAg5QNKKPHlRdRvd5tx%2F0lxhVjkxYf4xajAqU2W&amp;TOPIC_ID=131816" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761178s011lbl.pdf#page=26</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F55855049"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Alzheimer disease:</b> Treatment of Alzheimer disease in patients with mild cognitive impairment or mild dementia stage of disease, with confirmed presence of amyloid beta pathology prior to treatment initiation.</p></div>
<div class="block mst drugH1Div" id="F55871823"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Aducanumab may be confused with adalimumab.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55868958"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55868955"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F55871826"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies. The pharmacologic target of aducanumab (amyloid beta) is not present in rats, which may limit the relevance of animal data.</p>
<p style="text-indent:0em;margin-top:2em;">Aducanumab is a humanized monoclonal antibody (IgG<sub>1</sub>). Human IgG is known to cross the placenta; exposure is dependent upon the IgG subclass, maternal serum concentrations, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p></div>
<div class="block brc drugH1Div" id="F55871827"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if aducanumab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F55871852"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">PET or lumbar puncture to confirm presence of amyloid beta pathology (prior to initiation); brain MRI (prior to initiation [within 1 year], prior to infusion 5 [first dose of 6 mg/kg], infusion 7 [first dose of 10 mg/kg], infusion 9 [third dose of 10 mg/kg], and infusion 12 [sixth dose of 10 mg/kg]); monitor closely for clinical and MRI changes; monitor for symptoms suggestive of amyloid-related imaging abnormalities (ARIA) (eg, headache, altered mental status, dizziness, visual disturbance, seizure, nausea); MRI as indicated if ARIA symptoms present or asymptomatic ARIA observed (Hameed 2020; manufacturer’s labeling).</p></div>
<div class="block pha drugH1Div" id="F55871841"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Aducanumab is a monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. Aducanumab reduces amyloid beta plaques, the accumulation of which is a defining pathophysiological feature of Alzheimer disease.</p></div>
<div class="block phk drugH1Div" id="F55871842"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 9.63 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Degraded via catabolic pathways into small peptides and amino acids.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 24.8 days.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58847486"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aduhelm</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Aduhelm.1">
<a name="Aduhelm.1"></a>Aduhelm (aducanumab) [prescribing information]. Cambridge, MA: Biogen Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23578674">
<a name="23578674"></a>Barakos J, Sperling R, Salloway S, et al. MR imaging features of amyloid-related imaging abnormalities. <i>AJNR Am J Neuroradiol</i>. 2013;34(10):1958-1965. doi:10.3174/ajnr.A3500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/23578674/pubmed" id="23578674" target="_blank">23578674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35542991">
<a name="35542991"></a>Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. <i>J Prev Alzheimers Dis.</i> 2022;9(2):197-210. doi:10.14283/jpad.2022.30<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/35542991/pubmed" id="35542991" target="_blank">35542991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35099507">
<a name="35099507"></a>Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloid-related imaging abnormalities and β-amyloid-targeting antibodies: a systematic review. <i>JAMA Neurol</i>. 2022;79(3):291-304. doi:10.1001/jamaneurol.2021.5205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/35099507/pubmed" id="35099507" target="_blank">35099507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31827267">
<a name="31827267"></a>Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. <i>Nat Rev Neurol</i>. 2020;16(1):30-42. doi:10.1038/s41582-019-0281-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/31827267/pubmed" id="31827267" target="_blank">31827267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34747986">
<a name="34747986"></a>Hall JN, Mormino E, Ng A, et al. Six recurrent amyloid-related imaging abnormality episodes in a patient treated with aducanumab. <i>JAMA Neurol</i>. 2022;79(1):87-89. doi:10.1001/jamaneurol.2021.3933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/34747986/pubmed" id="34747986" target="_blank">34747986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32206755">
<a name="32206755"></a>Hameed S, Fuh JL, Senanarong V, et al. Role of fluid biomarkers and PET imaging in early diagnosis and its clinical implication in the management of Alzheimer's disease. <i>J Alzheimers Dis Rep</i>. 2020;4(1):21-37. doi:10.3233/ADR-190143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/32206755/pubmed" id="32206755" target="_blank">32206755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child.<i> Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28956123">
<a name="28956123"></a>Martens RM, Bechten A, Ingala S, et al. The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study. <i>Eur Radiol</i>. 2018;28(3):1215-1226. doi:10.1007/s00330-017-5022-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/28956123/pubmed" id="28956123" target="_blank">28956123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol.</i> 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21784348">
<a name="21784348"></a>Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. <i>Alzheimers Dement</i>. 2011;7(4):367-385. doi:10.1016/j.jalz.2011.05.2351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aducanumab-drug-information/abstract-text/21784348/pubmed" id="21784348" target="_blank">21784348</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 131816 Version 43.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
